Clinical information and FLT3 mutation data for individual FLT3/WT study patients
Patient no. . | Age, y . | WBCs per mm3 . | Cytogenetics . | FAB . |
|---|---|---|---|---|
| W-1 | 1.9 | 74 300 | del(11)(q23q25) | M4 |
| W-2* | 1.3* | 202 500* | NA* | M5* |
| W-3 | 19.1 | 2 500 | NA | M0 |
| W-4 | 19.5 | 27 400 | Hypodiploid | M1 |
| W-5 | 17.5 | 178 200 | t(9;11)(p22;q23) | M5 |
| W-6* | 0.7* | 6 900* | t(11;12)(q23;p13)* | M5* |
| W-7 | 6.6 | 44 600 | NA | M4 |
| W-8 | 1.4 | 3 500 | NA | M5 |
| W-9 | 13.9 | 3 600 | NA | M2 |
| W-10 | 10.8 | 107 700 | t(16;16))(p13;q22) | M2 |
| W-11 | 0.5 | 116 800 | NA | M5 |
| W-12 | 12.0 | 1 100 | t(11;19)(q23;p13) | M7 |
| W-13* | 5.8* | 32 800* | inv(16)(p13q22)* | M4* |
| W-14* | 7.8* | 14 500* | t(9;11)(p22;q23)* | M5* |
Patient no. . | Age, y . | WBCs per mm3 . | Cytogenetics . | FAB . |
|---|---|---|---|---|
| W-1 | 1.9 | 74 300 | del(11)(q23q25) | M4 |
| W-2* | 1.3* | 202 500* | NA* | M5* |
| W-3 | 19.1 | 2 500 | NA | M0 |
| W-4 | 19.5 | 27 400 | Hypodiploid | M1 |
| W-5 | 17.5 | 178 200 | t(9;11)(p22;q23) | M5 |
| W-6* | 0.7* | 6 900* | t(11;12)(q23;p13)* | M5* |
| W-7 | 6.6 | 44 600 | NA | M4 |
| W-8 | 1.4 | 3 500 | NA | M5 |
| W-9 | 13.9 | 3 600 | NA | M2 |
| W-10 | 10.8 | 107 700 | t(16;16))(p13;q22) | M2 |
| W-11 | 0.5 | 116 800 | NA | M5 |
| W-12 | 12.0 | 1 100 | t(11;19)(q23;p13) | M7 |
| W-13* | 5.8* | 32 800* | inv(16)(p13q22)* | M4* |
| W-14* | 7.8* | 14 500* | t(9;11)(p22;q23)* | M5* |
WBC indicates white blood cells; FAB, French-American-British classification; ITD/WT, FLT3/ITD to wild-type allelic ratio; NA, not available; bp, base pair insertion; and Nt, nucleotide.
Indicates CEP-701 responder.